Patent
The present invention relates to live attenuated Salmonella strains comprising a first attenuating mutation, that are not capable of making functional RecA. The invention also relates to these bacteria for use in vaccines. Furthermore, the invention relates to vaccines based upon these bacteria, to the use of such bacteria in the manufacture of vaccines and to methods for the preparation of such vaccines.
1. An attenuated Salmonella strain, wherein the strain:
comprises a first attenuating mutation decreasing the LD 50 of said strain at least 50,000 times when compared to wild-type strain,
comprises a mutation that prohibits the strain from making a functional RecA protein, and
is a Salmonella gallinarum 9R strain.
2. An attenuated Salmonella strain, wherein the strain is a Salmonella gallinarum 9R-RecA strain of which a sample is deposited with the Centraalbureau voor Schimmelcultures under deposit number CBS 108964.
3. An attenuated Salmonella strain, wherein the strain:
comprises a first attenuating mutation decreasing the LD 50 of said strain at least 50,000 times when compared to wild-type strain,
comprises a mutation that prohibits the strain from making a functional RecA protein, and
is a Salmonella typhimurium SL3261 strain.
4. A vaccine for combating Salmonella infection, comprising:
an attenuated Salmonella strain according to claim 1 , and
a pharmaceutically acceptable carrier.
5. A vaccine for combating Salmonella infection, comprising:
an attenuated Salmonella strain according to claim 2 , and
a pharmaceutically acceptable carrier.
6. A vaccine for combating Salmonella infection, comprising:
an attenuated Salmonella strain according to claim 3 , and
a pharmaceutically acceptable carrier.
7. A method for the preparation of a vaccine for combating Salmonella infection, comprising admixing:
an attenuated Salmonella strain according to claim 1 , and
a pharmaceutically acceptable carrier.
8. A method for the preparation of a vaccine for combating Salmonella infection, comprising admixing:
an attenuated Salmonella strain according to claim 2 , and
a pharmaceutically acceptable carrier.
9. A method for the preparation of a vaccine for combating Salmonella infection, comprising admixing:
an attenuated Salmonella strain according to claim 3 , and
a pharmaceutically acceptable carrier.